BioNTech SE – ADR (NASDAQ: BNTX) stock surges 14.97% on August 9^th, 2021 and corrected over 5% on August 10^th, 2021 (as of 1:13:51 PM UTC-4 · USD; Source: Google finance). The company posted better than expected results for the second quarter of FY 21. BioNTech pegged the vaccine’s cumulative global sales at more than 1 billion doses as of July 21. The company has signed agreements with Pfizer to supply about 2.2 billion doses this year and more than 1 billion doses in 2022 and beyond are likely to yield about 15.9 billion euros in 2021 revenue. The manufacturing capacity for the vaccine is projected to increase to 3 billion doses annually by yearend 2021 and up to 4 billion next year.

Further, in May 2021, BioNTech and Pfizer had announced the expansion of emergency use authorizations, conditional marketing authorizations or equivalent for adolescents 12 years of age and older in the United States, European Union and Canada. The company has granted authorizations for adolescents 12 years of age and older in additional countries. Meanwhile, in July 2021, BioNTech and Pfizer began a Phase 3 clinical trial for evaluation of the safety, tolerability and efficacy of a 30µg booster dose of BNT162b2 compared to placebo in approximately 10,000 participants aged 16 years and older who have previously received two doses of BNT162b2 at least six months prior to randomization. The trial is being conducted in the United States, Brazil and South Africa.

Moreover, BNTX has increased the development of a broad oncology pipeline which has now advanced 15 product candidates in 18 ongoing trials. Six clinical trials, that includes the two randomized Phase 2 clinical trials for FixVac programs, BNT111 and BNT113, have started in 2021. In the second quarter of 2021, BNTX had started first-in-human Phase 1 trials for the neoantigen specific T cell therapy, BNT221, and for a second RiboCytokine program, BNT152+153. BioNTech anticipates to further advance its oncology pipeline in the second half of 2021 with BNT122 expected to move into a randomized Phase 2 trial, and two further preclinical programs to move into Phase 1 trials.

BNTX in the second quarter of FY 21 has reported the adjusted earnings per share of 10.77 euros, beating the analysts’ estimates for the adjusted earnings per share of 6.94 euros, according to analysts polled by Capital IQ. The company had reported the adjusted revenue of 5.31 billion euros in the second quarter of FY 21, beating the analysts’ estimates for revenue of 3.27 billion euros.